:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/RLJSXSJJIVDTTKBTYHESGYDXJE.jpg)
European Medicines Agency says omicron cases are mostly “mild”
The European Medicines Agency (EMA) said Thursday that most cases of the omicron variant of the coronavirus in the European Union appeared to be “mild.”
European Medicines Agency
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/MU7VL25KTJEZ7E63MDFGP3VCFI.jpg)
The EMA estimates that adapting the vaccines to the omicron variant will take between three and four months
The director of the European Medicines Agency, Emer Cooke, said on Tuesday that the agency has plans to accelerate the adaptation of vaccines to the
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/6VN2GLIVB5CYHBYPIM4KGT7KJE.jpg)
The EMA evaluates approval of the monoclonal antibody sotrovimab for COVID-19
Lima, November 18, 2021Updated on 11/18/2021 03:22 pm The European Medicines Agency (EMA) received on Thursday a request from the British pharmaceutical company GlaxoSmithKline to
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/LL3YO23635D2BNQF2ERNUQCKP4.jpg)
European Medicines Agency begins evaluating Pfizer vaccine for children 5 to 11 years old
Lima, October 18, 2021Updated 10/18/2021 10:20 am The European Medicines Agency (EMA) today announced the beginning of the evaluation of the Pfizer-BioNTech vaccine against COVID-19
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/DMFV5UX75JCDJGBN6IYN3TORHE.jpg)
European Medicines Agency approves third dose of Pfizer vaccine for people over 18 years of age
The European Medicines Agency approved on Monday a third booster dose of the vaccine against COVID-19 by Pfizer / BioNTech for people over 18 years
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/GXYDHHAMWVGWHCFSEGHQBROBYU.jpg)
The European Medicines Agency is studying today the need for the third dose against COVID-19
The experts of the European Medicines Agency (EMA) analyzed this Monday the data provided by the pharmaceutical companies to determine the need for a booster
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/OPDJRZJ3SNBQVFWMFD5K4UN6T4.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/56COWKPMZ5BWTO5L7XHDW4XX4I.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/J6J3NQGC35AH5EJNZESIU4J6NQ.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/LRULJ2IG6NCTVG45H7RKXALHKU.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/C4NQTY7EBFFIVMR6NFEE5WTENM.jpg)
